Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672246 | 0.80 | PRMT5 (0.38) | KDM4EPSMB8TSHRCCR2ALDH1A1 | |
| SCHEMBL5672286 | 0.79 | CCR2 (0.37) | KDM4EPSMB8TSHRCCR2ALDH1A1 | |
| SCHEMBL20853335 | 0.78 | CASR (0.42) | LMNARAB9AKDM4ECYP1A2TSHR | |
| SCHEMBL476703 | 0.75 | CCR2 (0.35) | KDM4EPSMB8CCR2ALDH1A1TP53 | |
| SCHEMBL5673448 | 0.75 | CMA1 (0.51) | LMNARAB9AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL10993351 | 0.75 | KDM4E (0.54) | LMNARAB9AKDM4ECYP1A2TSHR | |
| SCHEMBL20853011 | 0.74 | CCR2 (0.38) | LMNAKDM4ETSHRCCR2ALDH1A1 | |
| SCHEMBL20853309 | 0.73 | CCR2 (0.37) | KDM4ECYP1A2TSHRCYP3A4CYP2C9 | |
| SCHEMBL18000099 | 0.72 | PRMT5 (0.44) | PSMB8CYP1A2CYP2C9CCR2ALDH1A1 | |
| SCHEMBL20853278 | 0.72 | CCR2 (0.48) | LMNARAB9ACYP1A2TSHRCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| CN-1234688-C | 3-aroyl indoles and their use as CB2Use of receptor agonists | SANOFI ANVANT (FR) | 2006-01-04 | — | — | CN | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| CN-1483023-A | 3-arylindole derivatives and their use as cb2 receptor agonists | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-03-17 | — | — | CN | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | LMNA 3429/4885RAB9A 2028/4885KDM4E 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.